Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria
<i>Background and Objectives</i>: The neurofilament light chain (NfL) is a biomarker for neuro-axonal injury in various acute and chronic neurological disorders, including Alzheimer’s disease (AD). We here investigated the cross-sectional and longitudinal associations between baseline se...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/3/433 |
| _version_ | 1797445275160150016 |
|---|---|
| author | Daniela Kern Michael Khalil Lukas Pirpamer Arabella Buchmann Edith Hofer Peter Dal-Bianco Elisabeth Stögmann Christoph Scherfler Thomas Benke Gerhard Ransmayr Reinhold Schmidt |
| author_facet | Daniela Kern Michael Khalil Lukas Pirpamer Arabella Buchmann Edith Hofer Peter Dal-Bianco Elisabeth Stögmann Christoph Scherfler Thomas Benke Gerhard Ransmayr Reinhold Schmidt |
| author_sort | Daniela Kern |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: The neurofilament light chain (NfL) is a biomarker for neuro-axonal injury in various acute and chronic neurological disorders, including Alzheimer’s disease (AD). We here investigated the cross-sectional and longitudinal associations between baseline serum NfL (sNfL) levels and cognitive, behavioural as well as MR volumetric findings in the Prospective Dementia Registry Austria (PRODEM-Austria). <i>Materials and Methods</i>: All participants were clinically diagnosed with AD according to NINCDS-ADRDA criteria and underwent a detailed clinical assessment, cognitive testing (including the Mini Mental State Examination (MMSE) and the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)), the neuropsychiatric inventory (NPI) and laboratory evaluation. A total of 237 patients were included in the study. Follow-up examinations were done at 6 months, 1 year and 2 years with 93.3% of patients undergoing at least one follow-up. We quantified sNfL by a single molecule array (Simoa). In a subgroup of 125 subjects, brain imaging data (1.5 or 3T MRI, with 1 mm isotropic resolution) were available. Brain volumetry was assessed using the FreeSurfer image analysis suite (v6.0). <i>Results</i>: Higher sNfL concentrations were associated with worse performance in cognitive tests at baseline, including CERAD (B = −10.084, SE = 2.999, <i>p</i> < 0.001) and MMSE (B = −3.014, SE = 1.293, <i>p</i> = 0.021). The sNfL levels also correlated with the presence of neuropsychiatric symptoms (NPI total score: r = 0.138, <i>p</i> = 0.041) and with smaller volumes of the temporal lobe (B = −0.012, SE = 0.003, <i>p</i> = 0.001), the hippocampus (B = −0.001, SE = 0.000201, <i>p</i> = 0.013), the entorhinal (B = −0.000308, SE = 0.000124, <i>p</i> = 0.014), and the parahippocampal cortex (B = −0.000316, SE = 0.000113, <i>p</i> = 0.006). The sNfL values predicted more pronounced cognitive decline over the mean follow-up period of 22 months, but there were no significant associations with respect to change in neuropsychiatric symptoms and brain volumetric measures. <i>Conclusions</i>: the sNfL levels relate to cognitive, behavioural, and imaging hallmarks of AD and predicts short term cognitive decline. |
| first_indexed | 2024-03-09T13:23:26Z |
| format | Article |
| id | doaj.art-7cd45499937447c49d2e97eac18f63ee |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T13:23:26Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-7cd45499937447c49d2e97eac18f63ee2023-11-30T21:26:57ZengMDPI AGMedicina1010-660X1648-91442022-03-0158343310.3390/medicina58030433Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry AustriaDaniela Kern0Michael Khalil1Lukas Pirpamer2Arabella Buchmann3Edith Hofer4Peter Dal-Bianco5Elisabeth Stögmann6Christoph Scherfler7Thomas Benke8Gerhard Ransmayr9Reinhold Schmidt10Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, AustriaDepartment of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, AustriaDepartment of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, AustriaDepartment of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, AustriaDepartment of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, AustriaDepartment of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, AustriaDepartment of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, AustriaDepartment of Neurology, Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, AustriaDepartment of Neurology, Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, AustriaDepartment of Neurology 2, Faculty of Medicine, Kepler University Hospital, Krankenhausstraße 9, 4020 Linz, AustriaDepartment of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, Austria<i>Background and Objectives</i>: The neurofilament light chain (NfL) is a biomarker for neuro-axonal injury in various acute and chronic neurological disorders, including Alzheimer’s disease (AD). We here investigated the cross-sectional and longitudinal associations between baseline serum NfL (sNfL) levels and cognitive, behavioural as well as MR volumetric findings in the Prospective Dementia Registry Austria (PRODEM-Austria). <i>Materials and Methods</i>: All participants were clinically diagnosed with AD according to NINCDS-ADRDA criteria and underwent a detailed clinical assessment, cognitive testing (including the Mini Mental State Examination (MMSE) and the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)), the neuropsychiatric inventory (NPI) and laboratory evaluation. A total of 237 patients were included in the study. Follow-up examinations were done at 6 months, 1 year and 2 years with 93.3% of patients undergoing at least one follow-up. We quantified sNfL by a single molecule array (Simoa). In a subgroup of 125 subjects, brain imaging data (1.5 or 3T MRI, with 1 mm isotropic resolution) were available. Brain volumetry was assessed using the FreeSurfer image analysis suite (v6.0). <i>Results</i>: Higher sNfL concentrations were associated with worse performance in cognitive tests at baseline, including CERAD (B = −10.084, SE = 2.999, <i>p</i> < 0.001) and MMSE (B = −3.014, SE = 1.293, <i>p</i> = 0.021). The sNfL levels also correlated with the presence of neuropsychiatric symptoms (NPI total score: r = 0.138, <i>p</i> = 0.041) and with smaller volumes of the temporal lobe (B = −0.012, SE = 0.003, <i>p</i> = 0.001), the hippocampus (B = −0.001, SE = 0.000201, <i>p</i> = 0.013), the entorhinal (B = −0.000308, SE = 0.000124, <i>p</i> = 0.014), and the parahippocampal cortex (B = −0.000316, SE = 0.000113, <i>p</i> = 0.006). The sNfL values predicted more pronounced cognitive decline over the mean follow-up period of 22 months, but there were no significant associations with respect to change in neuropsychiatric symptoms and brain volumetric measures. <i>Conclusions</i>: the sNfL levels relate to cognitive, behavioural, and imaging hallmarks of AD and predicts short term cognitive decline.https://www.mdpi.com/1648-9144/58/3/433Alzheimer’sneurofilament light (NfL)biomarkerblood biomarkerdementia |
| spellingShingle | Daniela Kern Michael Khalil Lukas Pirpamer Arabella Buchmann Edith Hofer Peter Dal-Bianco Elisabeth Stögmann Christoph Scherfler Thomas Benke Gerhard Ransmayr Reinhold Schmidt Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria Medicina Alzheimer’s neurofilament light (NfL) biomarker blood biomarker dementia |
| title | Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria |
| title_full | Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria |
| title_fullStr | Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria |
| title_full_unstemmed | Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria |
| title_short | Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria |
| title_sort | serum nfl in alzheimer dementia results of the prospective dementia registry austria |
| topic | Alzheimer’s neurofilament light (NfL) biomarker blood biomarker dementia |
| url | https://www.mdpi.com/1648-9144/58/3/433 |
| work_keys_str_mv | AT danielakern serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT michaelkhalil serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT lukaspirpamer serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT arabellabuchmann serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT edithhofer serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT peterdalbianco serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT elisabethstogmann serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT christophscherfler serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT thomasbenke serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT gerhardransmayr serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria AT reinholdschmidt serumnflinalzheimerdementiaresultsoftheprospectivedementiaregistryaustria |